-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies’ DT120 Confidence and Psychedelic Tailwinds Might Change The Case For Investing In Definium Therapeutics (DFTX)

Simply Wall St·02/19/2026 11:21:38
Listen to the news
  • Jefferies recently began covering Definium Therapeutics, highlighting Phase IIb data showing a single dose of lead candidate DT120 achieved a 48% remission rate in generalized anxiety disorder and assigning strong confidence in its upcoming Phase III trials.
  • At the same time, strong late-stage results and regulatory progress for COMP360 at Compass Pathways have lifted sentiment across the psychedelics space, indirectly enhancing investor attention on Definium’s clinical pipeline.
  • Next, we’ll examine how Jefferies’ confidence in DT120’s Phase III prospects shapes Definium Therapeutics’ broader investment narrative.

Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

What Is Definium Therapeutics' Investment Narrative?

To own Definium Therapeutics, you have to believe that DT120 can translate its Phase IIb signal into successful Phase III outcomes and, eventually, an approvable product in generalized anxiety disorder and major depressive disorder. The Jefferies initiation, with its emphasis on a 48% remission rate and high confidence in upcoming Phase III trials, sharpens that core thesis and adds near-term attention to the stock, but it does not change the underlying binary nature of those readouts as the key 2026 catalysts. At the same time, Compass Pathways’ positive COMP360 data has boosted sentiment for psychedelic-based treatments more broadly, which may help Definium’s share price in the short term without reducing the fundamental scientific, regulatory, and financing risks that come with a pre-revenue company running four costly Phase III programs and posting sizeable ongoing losses.

However, investors should be aware of one risk in particular that could matter very quickly. Definium Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

DFTX 1-Year Stock Price Chart
DFTX 1-Year Stock Price Chart
Ten fair value estimates from the Simply Wall St Community span roughly US$23 to a very large upper bound, underscoring how differently people are sizing up DT120’s prospects and funding risk around those closely watched Phase III data readouts.

Explore 10 other fair value estimates on Definium Therapeutics - why the stock might be worth just $23.44!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

  • The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
  • We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
  • Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.